RU2008103608A - Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела - Google Patents

Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела Download PDF

Info

Publication number
RU2008103608A
RU2008103608A RU2008103608/15A RU2008103608A RU2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608/15 A RU2008103608/15 A RU 2008103608/15A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A
Authority
RU
Russia
Prior art keywords
therapeutic antibody
target antigen
sample
antibody
complex
Prior art date
Application number
RU2008103608/15A
Other languages
English (en)
Russian (ru)
Inventor
Хельмут ЛЕНЦ (DE)
Хельмут ЛЕНЦ
Вернер ШОЙЕР (DE)
Вернер ШОЙЕР
Мартина ТИР (DE)
Мартина ТИР
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU2008103608A publication Critical patent/RU2008103608A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2008103608/15A 2005-07-06 2006-07-05 Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела RU2008103608A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05014618.2 2005-07-06
EP05014618 2005-07-06
EP06004447.6 2006-03-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
RU2008103608A true RU2008103608A (ru) 2009-08-20

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008103608/15A RU2008103608A (ru) 2005-07-06 2006-07-05 Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела

Country Status (19)

Country Link
US (1) US20070009976A1 (cg-RX-API-DMAC10.html)
EP (2) EP1902315A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008545145A (cg-RX-API-DMAC10.html)
KR (1) KR20080016939A (cg-RX-API-DMAC10.html)
AR (1) AR053948A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006265275A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612591A2 (cg-RX-API-DMAC10.html)
CA (1) CA2613187A1 (cg-RX-API-DMAC10.html)
CR (1) CR9635A (cg-RX-API-DMAC10.html)
EC (1) ECSP088081A (cg-RX-API-DMAC10.html)
IL (1) IL188317A0 (cg-RX-API-DMAC10.html)
MA (1) MA29730B1 (cg-RX-API-DMAC10.html)
MX (1) MX2008000277A (cg-RX-API-DMAC10.html)
MY (1) MY157955A (cg-RX-API-DMAC10.html)
NO (1) NO20076662L (cg-RX-API-DMAC10.html)
NZ (1) NZ564471A (cg-RX-API-DMAC10.html)
RU (1) RU2008103608A (cg-RX-API-DMAC10.html)
TW (1) TWI312864B (cg-RX-API-DMAC10.html)
WO (1) WO2007003420A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
UA90480C2 (uk) * 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
WO2006039486A2 (en) 2004-10-01 2006-04-13 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック, インコーポレイテッド Her2陽性転移性乳癌の治療方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック, インコーポレイテッド 進行したher2発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック, インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
DE60233744D1 (de) * 2001-09-20 2009-10-29 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies

Also Published As

Publication number Publication date
AR053948A1 (es) 2007-05-23
US20070009976A1 (en) 2007-01-11
EP2194380A2 (en) 2010-06-09
TWI312864B (en) 2009-08-01
BRPI0612591A2 (pt) 2010-11-23
MY157955A (en) 2016-08-30
EP2194380A3 (en) 2010-07-14
JP2008545145A (ja) 2008-12-11
ECSP088081A (es) 2008-02-20
KR20080016939A (ko) 2008-02-22
CR9635A (es) 2008-02-20
WO2007003420A1 (en) 2007-01-11
NO20076662L (no) 2008-04-03
TW200741203A (en) 2007-11-01
IL188317A0 (en) 2008-04-13
EP1902315A1 (en) 2008-03-26
AU2006265275A1 (en) 2007-01-11
CA2613187A1 (en) 2007-01-11
MA29730B1 (fr) 2008-09-01
NZ564471A (en) 2010-04-30
MX2008000277A (es) 2008-03-24

Similar Documents

Publication Publication Date Title
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
CN110383068A (zh) 评估患者样品中uch-l1状态的改进方法
JP2008545145A5 (cg-RX-API-DMAC10.html)
CN110546513A (zh) 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
DK1668368T3 (da) Detektion af histon-modifikation i cellefrie nukleosomer
JP2020517306A5 (cg-RX-API-DMAC10.html)
WO2018175942A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
EP2194380A3 (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
RU2014103054A (ru) Применение антитела i-3859 для выявления и диагностики рака
Lei et al. Application of an immunomagnetic bead ELISA based on IgY for detection of circulating antigen in urine of mice infected with Schistosoma japonicum
JP4608432B2 (ja) 腫瘍マーカーとしてのn▲1▼,n▲12▼−ジアセチルスペルミン
WO2017125892A3 (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv
US20150198598A1 (en) Kit for diagnosing malignant melanoma
CN109313201B (zh) 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
EP3602069A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
JP2025503439A (ja) 血液試料におけるuch-l1、gfap及び他のバイオマーカーを決定するためのシステム及び方法
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
ATE493662T1 (de) Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker
EP4396587A1 (en) Methods and systems of diagnosing brain injury
RU2012126312A (ru) Маркерный белок для диабета типа 2
WO2024040238A3 (en) Method of diagnosing and treating prostate cancer using zinc finger protein-like 1 antibodies
EA202090834A1 (ru) Набор реагентов для выявления маркера эпителиальных карцином
TH86235A (th) การตรวจหาแอนติเจนเป้าหมายโดยไม่คำนึงว่ามีแอนติบอดีรักษาโรคที่สมนัยกันหรือไม่มีก็ได้